Consort flow diagram. Among the 80 patients assessed for eligibility, 63 were eventually randomized: 32 were allocated to and received DNM, whereas 31 were allocated to and received placebo. One patient from the placebo group was lost to follow-up, whereas 2 patients from the DNM group withdrew consent. The final analysis was made on an intent-to-treat basis.